COMPASS Pathways plc CMPS
8.60 USD +0.01 (+0.12%)
At closeNov 4, 2026, 7:52 PM EST
8.68 +0.08 +0.93%
After hours · Nov 4, 7:52 PM ET
8.05 Day range 8.88
4.88 52-week range 15.87
- YTD
- +24.64%
- 1 year
- +29.71%
- Market cap
- 1.22B
- EPS (ttm)
- -2.34
- Shares out
- 141.71M
- Forward P/E
- -6.00
- YTD return
- +24.64%
- 1-year return
- +29.71%
- Volume
- 5.25M
- Avg volume
- 2.98M
- Open
- 8.53
- Previous close
- 8.59
- Day's range
- 8.05 – 8.88
- 52-week range
- 4.88 – 15.87
- Analysts
- Strong Buy
- Price target
- 23.75 (+176.2%)
- Earnings date
- Mar 4, 2027
2Y +4.08 (+90.27%)
Key statistics
- Enterprise value
- 827.71M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 35.62M
- Total cash
- 443.98M
- Total debt
- 54.39M
- Return on equity
- -296.45%
- Short % of float
- 12.63%
- 50-day average
- 12.70
- 200-day average
- 10.41
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.75 +176.2% upside
Now 8.60
- Target (low)
- 13.00
- Target (mean)
- 23.75
- Target (high)
- 65.00
Ratings (0m) 16 15 buy · 1 hold · 0 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate -0.3875.
Financials — quick view
CMPS Revenue — quarterly 0
CMPS Net income — quarterly -253.79M
CMPS EPS — quarterly -1.88
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | -0.40248 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.39 | -0.31 | +0.08 | +20.51% |
| Aug 5, 2026 | Jun 30, 2026 | -0.46 | -0.36 | +0.10 | +21.74% |
| May 13, 2026 | Mar 31, 2026 | -0.45 | -0.30 | +0.15 | +33.33% |
| Mar 24, 2026 | Dec 31, 2025 | -0.41 | -1.00 | -0.59 | -143.90% |
| Nov 4, 2025 | Sep 30, 2025 | -0.40 | -1.44 | -1.04 | -260.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | BTIG | reit | Buy | Buy |
| Aug 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 6, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 6, 2026 | B. Riley Securities | main | Buy | Buy |
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United Kingdom
- Website
- compasspathways.com
News
Wells Fargo Maintains Equal-Weight on Compass Pathways, Lowers Price Target to $10 
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th 
Compass Pathways: 3 Key Takeaways for Long-Term Investors 
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript 
Compass Pathways Q3 Earnings Call Highlights 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Compass Pathways Q3 EPS $(0.31) Beats $(0.43) Estimate 
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights 
Compass Pathways Issues New Report Summarizing Findings From National Survey Of People Living With TRD And Caregivers On The Burden Of Prolonged Depressive Episodes Without Meaningful Relief 
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
Your note
Sign in to keep a note on CMPS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LOXAM TERI | Chief Financial Officer | Stock Award(Grant) | Mar 25, 2026 | 152,002 |
| NATH KABIR | Chief Executive Officer | Stock Award(Grant) | Mar 25, 2026 | 366,990 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 8.78% | 12,161,496 | 104.59M | Jun 29, 2026 |
| RTW Investments LP | 7.73% | 10,700,974 | 92.03M | Jun 29, 2026 |
| BIT Capital GmbH | 4.58% | 6,348,797 | 54.60M | Jun 29, 2026 |
| Tang Capital Management, LLC | 3.61% | 5,000,000 | 43.00M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.23% | 4,470,485 | 38.45M | Jun 29, 2026 |
| Marshall Wace LLP | 3.13% | 4,328,682 | 37.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.32% | 4,591,088 | 39.48M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.64% | 886,679 | 7.63M | Sep 29, 2026 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.35% | 482,715 | 4.15M | Sep 29, 2026 |
| ROYCE FUND-Royce Smaller-Companies Growth Fund | 0.13% | 178,000 | 1.53M | Jun 29, 2026 |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 0.12% | 166,501 | 1.43M | Aug 30, 2026 |
| Goldman Sachs Trust-Goldman Sachs Small Cap Growth Fund | 0.11% | 152,301 | 1.31M | Aug 30, 2026 |